Serum Institute of India Pvt., the world’s largest vaccine maker, is expanding its production capacity. The company expects sales of life-saving vaccines, including those for malaria and cervical cancer, to double in the next five years.
Increasing Production Capacity
Serum Institute currently has the capacity to produce 3 billion doses of various vaccines annually. However, it only sells about 1.5 billion doses each year. The Pune-based firm forecasts a significant increase in demand. “As countries increase their health-care budgets, you’re going to see a huge uptake of vaccines that can prevent a lot of diseases,” said Serum’s Chief Executive Officer Adar Poonawalla. He emphasized, “Vaccines have been proven to be the most efficient tool for prevention.”
Poonawalla is particularly optimistic about the company’s new vaccines for malaria and cervical cancer. Serum has the capacity to produce 100 million doses of each. The malaria vaccine, R21/Matrix-M, has started to gain traction. Serum shipped the first batch to Africa in May. This vaccine is the second malaria shot authorized for children worldwide.
Addressing Vaccine Shortages
Despite the initial rollout, Poonawalla anticipates it will take about two years for demand to meet supply. Meanwhile, there is a global shortage of vaccines against the human papilloma virus (HPV), which can cause cervical cancer. Only a few manufacturers can produce HPV shots due to their complexity. “Only a few manufacturers can produce the HPV shots because it’s very complicated and difficult to make,” said Poonawalla. Serum plans to supply millions of doses of its HPV vaccine, Cervavac, at a discounted rate to the Indian government as part of the universal immunisation programme. Poonawalla also aims to sell the vaccine overseas.
Expanding Vaccine Portfolio
Serum is also working on vaccines to combat four strains of the dengue virus and various flu viruses. “It is something we need to be wary about because there are already 14 different flu strains,” Poonawalla explained. He noted that while a global flu pandemic seems unlikely in the near future, localized outbreaks can still cause significant harm. In April, Serum signed a licensing agreement with the University of Oxford to produce and deliver a chimeric protein-based vaccine against Meningitis-B, an infection affecting the brain and spinal cord.
Also read: Infosys Collaborates with Nihon Chouzai to Enhance Digital Healthcare Access in Japan
Overcoming Past Challenges
The company faced significant challenges during the COVID-19 pandemic. Serum was responsible for producing AstraZeneca Plc’s Covid-19 vaccine in India. During the pandemic’s height, the company struggled to meet the overwhelming demand for Covishield supplies. They faced a fire at their production facility, a local ban on exports, and shortages of key raw materials from the US. Despite these hurdles, Poonawalla remains focused on improving global vaccine readiness. “If we’re more transparent and open with exchanging information with one another, I think you can get ahead of the curve,” he said. “You can save a lot of lives.”
Future Preparedness
In January, Serum joined the Coalition for Epidemic Preparedness Innovations (CEPI). This global organization consists of governments, non-profits, vaccine manufacturers, and health experts. Created in 2017 after the Ebola virus outbreak, CEPI works to improve vaccine development and response to epidemic threats. Poonawalla highlighted the importance of this collaboration. “With CEPI, we are building up stockpiles and we are working on a 100-day mission, where you can go from a vaccine candidate to production to shipping within 100 days,” he said.
The Importance of Vaccines
The importance of vaccines in global health cannot be overstated. According to the World Health Organization (WHO), vaccines prevent 2-3 million deaths annually. They protect against diseases such as diphtheria, tetanus, pertussis, influenza, and measles. With the expansion of its production capacity, Serum Institute aims to significantly contribute to these efforts. The company’s growth is poised to meet the increasing global demand for vaccines.
The Road Ahead
Serum Institute’s efforts align with global health goals, such as those outlined by the United Nations. The UN’s Sustainable Development Goal 3 aims to ensure healthy lives and promote well-being for all at all ages. This includes ending epidemics of AIDS, tuberculosis, malaria, and other communicable diseases by 2030. Serum’s increased production capacity and innovative vaccine development play a crucial role in achieving these targets.
Conclusion
The expansion of Serum Institute of India’s production capacity marks a significant milestone in global health. By doubling its vaccine sales in the next five years, the company aims to meet the growing demand for life-saving vaccines. From malaria and cervical cancer to dengue and flu, Serum’s diverse vaccine portfolio addresses critical health challenges. The company’s collaboration with CEPI and its commitment to transparency and innovation further strengthen its role in global health preparedness.
Serum Institute’s proactive approach ensures it remains at the forefront of vaccine production and distribution. As countries worldwide increase their healthcare budgets, Serum’s efforts will contribute to a healthier and more resilient global population. The future looks promising as the company continues to deliver on its mission to save lives through vaccination.
